Details

Autor(en) / Beteiligte

• Canaud, Guillaume
• Bienaimé, Frank
• Tabarin, Fanny
• Bataillon, Guillaume
• Seilhean, Danielle
• Noël, Laure-Hélène
• Dragon-Durey, Marie-Agnès
• Snanoudj, Renaud
• Friedlander, Gérard
• Halbwachs-Mecarelli, Lise
• Legendre, Christophe
• Terzi, Fabiola

Titel

Inhibition of the mTORC Pathway in the Antiphospholipid Syndrome

Ist Teil von

• The New England journal of medicine, 2014-07, Vol.371 (4), p.303-312

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2014

Quelle

MEDLINE

Beschreibungen/Notizen

• This study shows that the mTORC pathway is central to the antiphospholipid syndrome. Among patients with kidney transplants and antiphospholipid syndrome, 70% of those treated with sirolimus had long-term functioning allografts versus 12% of those not treated with sirolimus. The antiphospholipid syndrome is an autoimmune disease characterized by the presence of circulating antiphospholipid antibodies that result in vascular thrombosis and obstetrical complications. 1 The syndrome may be isolated or may occur in association with autoimmune disorders, such as systemic lupus erythematosus. Thrombotic events represent the major complication of the antiphospholipid syndrome, 2 and to date, long-term anticoagulation has been the only treatment shown to reduce vascular complications. However, that regimen does not prevent organ deterioration and death in high-risk patients, particularly those in whom catastrophic antiphospholipid syndrome develops. In addition to the thrombotic complications, vascular cellular infiltrates and fibrosis of the . . .